Durability of INI-containing regimens after switching from PI-containing regimens: a single-centre cohort of drug-experienced HIV-infected subjects.

Andrea GiacomelliAlice RanzaniLetizia OreniElena GervasiAngelica LupoAnna Lisa RidolfoMassimo GalliStefano Rusconi

Published in: Drug design, development and therapy (2019)

Switching from a PI- to an INI-containing regimen may be an option for patients under virological control. The patients switched to dolutegravir were less likely to discontinue the INI than those switched to raltegravir. Our findings support this therapeutic strategy and highlight the durability and efficacy of dolutegravir containing-regimens after switching from a PI-containing regimen.

Keyphrases

end stage renal disease
hiv infected
ejection fraction
antiretroviral therapy
chronic kidney disease
newly diagnosed
hiv infected patients
peritoneal dialysis
emergency department